Patients with RA treated with upadacitinib demonstrated improvements as early as week 1
Click Here to Manage Email Alerts
PHILADELPHIA — Patients with rheumatoid arthritis who were treated with upadacitinib demonstrated improvement in pain, fatigue and morning stiffness from week 1 through week 12, according to data presented at ACR Convergence 2022.
These improvements were seen notwithstanding prior treatment with TNF inhibitors.
“Our objective was to evaluate the impact of upadacitinib on patient-reported outcomes in patients with RA during the first 12 weeks of treatment using a mobile health application,” Leslie Harrold, MD, PhD, chief scientific officer of CorEvitas and associate professor of medicine at the University of Massachusetts Medical School, said during the presentation.
The study included 103 patients recruited through rheumatologists across 17 sites who participated in the CorEvitas RA Registry. Included patients initiated upadacitinib (Rinvoq, AbbVie) between July 2020 and October 2021. Patient-reported outcomes (PROs), which included Routine Assessment of Patient Index Data 3 (RAPID3), Patient-Reported Outcomes Measurement Information System-Fatigue 7a Short Form (PROMIS Fatigue-7a Short Form), and duration of morning joint stiffness, were collected at baseline, weeks 1 through 4, week 8 and week 12.
Of the 103 patients, 62.1% were previously treated with TNF inhibitors, according to the poster. At week 12, 51.4% (n = 53) completed the study, providing PROs in the mobile application. The average age of patients was 59.9 years, 81.6% were female, and mean RAPID3 score was 14.9.
At week 1, significant improvements in RAPID3 scores were observed among all patients initiating upadacitinib (95% CI, -3.5 - -1.5). These responses were maintained or improved through week 12 (95% CI, -6.3 - -3.1]), according to the poster. At week 8 and 12, improvements in pain, duration of morning stiffness and fatigue were also observed, with 37.5% of patients achieving RAPID3 low disease activity at week 12.
Beginning at week 1, RAPID3 disease activity improved minimally clinically important difference were achieved among the total study patient population. Furthermore, almost 50% of patients achieved these outcomes by week 4 and 60% by week 12, the researchers reported.
“In conclusion, in this real word cohort of RA patients, treatment with upadacitinib was associated with significant improvement in RAPID3, pain, morning stiffness and fatigue, regardless of prior TNF inhibitor experience,” Harrold said.
Collapse
Harrold L, et al. Abstract 1354. Presented at: ACR Convergence 2022; November 11-14, 2022; Philadelphia (hybrid meeting).
Read more about
Click Here to Manage Email Alerts